Teva (ADR) (TEVA)
Combines global generics scale with innovative neuroscience and immunology medicines.
Something off on this page? Send us feedback.
Combines global generics with innovative neuroscience and immunology medicines, biosimilars, and pharmacy brands across the United States, Europe, and International Markets. Revenue comes through high-volume medicine sales and branded products, with performance tied to regulatory approvals, pricing and reimbursement, manufacturing compliance, and patent outcomes.
Combines a global generics platform with innovative medicines, biosimilars, over-the-counter products, active ingredients, contract manufacturing, and drug out-licensing. Operations are organized across the United States, Europe, and International Markets.
Sells high-volume generics through pharmacy chains, distributors, wholesalers, health funds, and insurers, while commercializing AUSTEDO, AJOVY, UZEDY, and COPAXONE for neurological conditions. A large manufacturing and regulatory network supports broad product access, while focused development prioritizes neuroscience and immunology.
Execution depends on regulatory approvals, manufacturing compliance, reimbursement and pricing systems, patent and exclusivity outcomes, supply continuity, and commercial performance of newer medicines. Opioid-settlement supply and payment obligations and competition-law resolutions remain operating commitments.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | Initiate | Rating: —Target: — | Target: $50 |
| Sep 9, 2026 | Leerink Partners | Target | Target: — | Target: $45 |
| Sep 4, 2026 | UBS | Reiterate | Rating: —Target: $42 | Target: $48 |
| Aug 12, 2026 | Barclays | Reiterate | Rating: —Target: $40 | Target: $42 |
| Jul 28, 2026 | Piper Sandler | Reiterate | Rating: —Target: $42 | Target: $44 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.66B · Total debt $16.87B · Total assets $39.86B · Shareholders' equity $7.76B
- Revenue
- $4.14B
- Operating income
- $149.0M
- Net income
- −$576.0M
No dividends on record.
| Institutions | 63.15% | 735.87M ADS | |
|---|---|---|---|
| 715 holders · as of Jun 30, 2026 | |||
| Insiders | 0.15% | 1.71M ADS | |
| 20 holders · as of Sep 22, 2026 | |||
| Strategic holders | 4.92% | 57.38M ADS | |
| 1 holder · as of Jul 22, 2025 | |||
| Other | 31.78% | 370.32M ADS | |
| remainder | |||
1.17B ADS as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Capital Research Global InvestorsInstitution | 11.24% | 130.95M | filed Feb 14, 2020 |
BlackRock, Inc.Institution | 5.48% | 63.89M ADS | as of Jun 30, 2026 |
Phoenix Financial Ltd.Strategic | 4.92% | 57.38M | filed Jul 22, 2025 |
Harel Insurance Investments & Financial Services Ltd.Institution | 4.13% | 48.14M ADS | as of Jun 30, 2026 |
Phoenix Holdings Ltd.Institution | 3.68% | 42.93M ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 18, 2026 | Brian Savage | officer: Interim Chief Legal Officer | −7,342 | $38.85 |
| Sep 18, 2026 | Roberto Mignone | director | −367,600 | $39.06 |
| Aug 21, 2026 | Amir Weiss | officer: Chief Accounting Officer | −9,445 | $37.62 |
| Aug 21, 2026 | Ronit Satchi-Fainaro | director | −415 | $37.25 |
| Aug 17, 2026 | Evan Lippman | officer: EVP, Business Development | −18,600 | $36.57 |
- Viatris
Global generic medicines across the same major regions
- Dr. Reddy's Laboratories (ADR)
Generics and biosimilars spanning major international markets
- Amneal Pharmaceuticals
U.S. complex generics, injectables, and biosimilars
- Neurocrine Biosciences
INGREZZA directly challenges AUSTEDO in movement disorders
- Eli Lilly
Emgality challenges AJOVY in migraine prevention
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Teva (ADR) | $39.51 | −0.04% | $46.03B | 65.9 | 14.1 | 2.7 | −0.8% |
| Viatris | $17.19 | +0.06% | $20.01B | — | 6.7 | 1.4 | +4.9% |
| Dr. Reddy's Laboratories (ADR) | $12.44 | −1.07% | $10.47B | 30.2 | 33.2 | 3.0 | −15.5% |
| Amneal Pharmaceuticals | $19.02 | −2.46% | $6.23B | 40.0 | 19.1 | 2.0 | +9.9% |
| Neurocrine Biosciences | $139.93 | −1.63% | $14.30B | 20.9 | 15.3 | 4.2 | +39.5% |
| Eli Lilly | $1,160.35 | −0.84% | $1.10T | 39.3 | 28.4 | 13.8 | +47.7% |
| Median | 34.8 | 19.1 | 3.0 | +9.9% |